Isamu Okamoto

Isamu Okamoto is a leading thoracic oncologist in Japan with expertise spanning SCLC and EGFR-mutated NSCLC. He has contributed to clinical trials of immunotherapy regimens in SCLC in Japanese patient populations and co-investigates molecular markers predictive of SCLC treatment response. His work bridges global clinical trial participation with Japanese regulatory and healthcare context. He serves on Japanese academic lung cancer committees and contributes to ESMO and WCLC through international collaboration.